Nancy D. Lin, Vice President -Real World Insights & Evidence, joined Health Catalyst Life Sciences in September 2020. Dr. Lin is an epidemiologist with over 15 years of experience in clinical and pharmacoepidemiology research and specific experience in cross-institutional studies. Her primary research interests include application, utility, and methodologic considerations for the use of electronic health care data systems to enhance surveillance and assessment of medical products’ safety and effectiveness. Prior to joining Health Catalyst, Dr. Lin was a Senior Scientist in the Optum Insight Life Sciences, Epidemiology business. In that capacity, she provided scientific oversight over a range of retrospective and prospective cohort studies that leveraged health care claims, electronic health records, and data linkages (e.g., medical records, free-text clinical notes, registry data), and from 2013-2020, served as Optum’s Site Principal Investigator supporting the FDA Mini-Sentinel/Sentinel initiative. Dr. Lin also serves as Chair of the Science Committee for the Biologics and Biosimilars Collective Intelligence Consortium, a non-profit, multi-stakeholder scientific initiative engaged in real-world evidence generation on the utilization, safety, and effectiveness of biologics and biosimilars using a distributed network of health care organizations. Dr. Lin received a Doctor of Science in Epidemiology in 2004 and a Master of Science in Epidemiology in 2001 from the Harvard School of Public Health.